Recently, our research group investigated MYC, BCL2, and BCL6 rearrangements as well as pathogenic variants of MYD88 and CD79B in our Danish cohort of patients with DLBCL-NOS and HGBCL involving the ocular adnexa (n = 34), and showed that MYD88 pathogenic variants were present in 29% of the patients [20]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.